The Eteplirsen Approval: Former FDA Officials Weigh In On The Science
Executive Summary
A former CDER director, office director, division director, and supervisory reviewer agreed to comment for the record on the merits of the science that formed the basis of FDA’s accelerated approval of the Duchenne Muscular Dystrophy therapy Exondys 51.
You may also be interested in...
Lilly’s Failed Solanezumab: Could It Get Another Chance In A ‘Silicon Valley’ FDA?
Alzheimer drug’s development was discontinued after third disappointing Phase III trial, but given the kind of FDA commissioner candidates getting meetings with the President, maybe Lilly should reconsider.
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Pink Sheet’s Drug Review Profile looks at US FDA clinical memos opposing approval of Sarepta's Duchenne muscular dystrophy drug eteplirsen, revealing challenges patient advocates and agency face in transforming patient experiences into hard data that can be used for approvals.
The Gene Therapy Wave Is Here
The long-talked about wave of gene therapy approvals is beginning to reveal itself.